Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy
Links:
Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers…
https://acrabstracts.org/abstract/treat-to-target-approaches-in-early-psoriatic…
17-11-2024